GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
Rhea-AI Summary
GRI Bio (NASDAQ: GRI) will participate in the Corporate Connect Webinar Series hosted by Webull Financial, held virtually February 10-11, 2026. The company will deliver a live video webcast presentation on Wednesday, February 11, 2026 at 1:00 PM EST, presented by Marc Hertz, PhD.
Registration is available via the company's provided link. The presentation will cover GRI Bio's pipeline and corporate update for investors.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, GRI declined 17.05%, reflecting a significant negative market reaction. Argus tracked a trough of -11.3% from its starting point during tracking. Our momentum scanner triggered 20 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $784K from the company's valuation, bringing the market cap to $4M at that time. Trading volume was very high at 3.4x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
GRI is up 1.54% while several biotech peers such as ADTX (-9.59%), PALI (-4.82%) and TTNP (-3.96%) are down, suggesting stock-specific dynamics rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 04 | Financial & clinical update | Positive | +1.5% | Reiterated 2025 results, stronger cash to fund operations into Q1 2027. |
| Jan 28 | Clinical data update | Positive | -22.7% | New Phase 2a RNA‑seq data showing favorable antifibrotic gene expression signals. |
| Jan 26 | Patent issuance | Positive | -1.5% | New U.S. patent for proprietary pyrrolidine, piperidine and azepane compounds. |
| Jan 21 | Reverse stock split | Negative | -4.2% | 1-for-28 reverse split aimed at regaining Nasdaq minimum bid compliance. |
| Jan 08 | Clinical data update | Positive | -4.7% | Phase 2a IPF data showing iNKT inhibition and multiple antifibrotic signals. |
Recent history shows multiple instances where positive clinical or IP news coincided with negative price reactions, while balance-sheet strengthening and the reverse split aligned more with positive or defensive trading.
Over the past month, GRI reported strengthened finances with $8.2M year-end cash plus $6.5M raised in January 2026, alongside positive Phase 2a data for GRI-0621 in IPF and progress on GRI-0803. Additional gene expression and flow cytometry data supported disease‑modifying potential, and a new U.S. composition‑of‑matter patent expanded its IP. A 1-for-28 reverse split and Nasdaq compliance updates framed listing risk. Today’s conference participation fits this ongoing visibility and funding narrative.
Regulatory & Risk Context
An effective Form S-3 shelf filed on 2026-01-29 allows GRI Bio to offer up to $250,000,000 of various securities over time, with terms set in future prospectus supplements. Net proceeds are expected to support general corporate purposes, including working capital and administrative needs.
Market Pulse Summary
The stock dropped -17.1% in the session following this news. A negative reaction despite this visibility event would fit a pattern where prior positive updates, including clinical and patent milestones, sometimes preceded weak price action. The stock trades far below its $311.36 52‑week high and under the $39.46 200‑day MA, against a backdrop of going‑concern language and substantial financing capacity under a $250,000,000 shelf. Investors may have focused on dilution and balance‑sheet risks rather than webinar exposure.
AI-generated analysis. Not financial advice.
– Live video webcast on Wednesday, February 11th at 1:00 PM EST
LA JOLLA, CA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it will participate in the Corporate Connect Webinar Series hosted by Webull Financial being held virtually February 10-11, 2026.
Details of the presentation are as follows:
Date and Time: Wednesday, February 11, 2026 at 1:00 PM EST
Presenter: Marc Hertz, PhD, President, Chief Executive Officer and Director
Registration Link: Here
About Webull Financial
Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-edge technology. With low-cost trading on a wide range of assets, advanced charting tools, and real-time market data, Webull is revolutionizing the way individuals approach investing. The user-centric approach and commitment to staying at the forefront of industry trends underscore the mission to provide a seamless and rewarding experience for traders of all levels. Through the Webull Group, Webull Financial and its affiliates combine to serve tens of millions of users from over 180 countries worldwide. Securities and futures trading is offered to customers by Webull Financial LLC ("Webull Financial"), a broker-dealer registered with the Securities and Exchange Commission (SEC) and a futures commission merchant registered with the Commodity Futures Trading Commission (CFTC). Webull Financial is a member of the Financial Industry Authority (FINRA), the National Futures Association (NFA), and the Securities Investor Protection Corporation (SIPC). All investing is subject to risk, including the possible loss of principal. For more information about Webull, visit www.webull.com.
About GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of Natural Killer T (“NKT”) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT (“iNKT”) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an RARβγ agonist shown to inhibit the activity of key immune cells, like iNKT cell activity, and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 diverse NKT (“dNKT”) agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions. These forward-looking statements are based on the Company’s current beliefs and expectations. Forward-looking statements include, but are not limited to, statements regarding: the Company’s expectations with respect to development and commercialization of the Company’s product candidates, the timing of initiation or completion of clinical trials and availability of resulting data, the potential benefits and impact of the Company’s clinical trials and product candidates and any implication that the data or results observed in preclinical trials or earlier studies, topline or interim data or trials will be indicative of results of later studies or clinical trials or final data, that final data will be indicative of a proof-of-concept, the Company’s beliefs and expectations regarding potential shareholder value and future financial performance, the Company’s beliefs about the timing and outcome of regulatory approvals and potential regulatory approval pathways and the Company’s expected future milestones. Actual results may differ from the forward-looking statements expressed by the Company in this press release and consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, without limitation: (1) the inability to maintain the listing of the Company’s common stock on The Nasdaq Capital Market and to comply with applicable listing requirements; (2) changes in applicable laws or regulations; (3) the inability of the Company to raise financing in the future; (4) the success, cost and timing of the Company’s product development activities; (5) the inability of the Company to obtain and maintain regulatory clearance or approval for its respective products, and any related restrictions and limitations of any cleared or approved product; (6) the inability of the Company to identify, in-license or acquire additional technology; (7) the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently developing; (8) the size and growth potential of the markets for the Company’s products and services, and their respective ability to serve those markets, either alone or in partnership with others; (9) that later data or clinical trials may be inconsistent with or contrary to data and observations to date, including that later data may not indicate a proof-of-concept or patient benefit; (10) inaccuracy in the Company’s estimates regarding expenses, future revenue, capital requirements and needs for and the ability to obtain additional financing; (11) the Company’s ability to protect and enforce its intellectual property portfolio, including any newly issued patents and its ability to obtain any expected patent term extensions, adjustments, exclusivities or disclaimers; and (12) other risks and uncertainties indicated from time to time in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including the risks and uncertainties described in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K filed with the SEC on March 14, 2025 and subsequently filed reports. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
GRI@jtcir.com
FAQ
When will GRI Bio (GRI) present at the Webull Corporate Connect Webinar Series?
Who is presenting for GRI Bio (GRI) at the February 11, 2026 webcast?
How can investors register for GRI Bio's (GRI) Webull webinar on February 11, 2026?
What topics will GRI Bio (GRI) cover in the Webull Corporate Connect presentation?
Will GRI Bio's (GRI) Webull presentation be available as a live webcast?
Is the GRI Bio (GRI) Webull event open to public investors or by invitation?
